Author

akbar molazahi

OUTCOMES OF CORONAVIRUS DISEASE 2019 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND THE INFLUENCE OF IBD-RELATED MEDICATIONS– A DANISH PROSPECTIVE POPULATION-BASED COHORT STUDY
OUTCOMES OF CORONAVIRUS DISEASE 2019 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND THE INFLUENCE OF IBD-RELATED MEDICATIONS– A DANISH PROSPECTIVE POPULATION-BASED COHORT STUDY

akbar molazahi  et al.

THE REAL-WORLD EFFICACY AND SAFETY OF VEDOLIZUMAB IN BIO-NAïVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE - AN INTERIM ANALYSIS FROM A DANISH NATIONAL COHORT STUDY
THE REAL-WORLD EFFICACY AND SAFETY OF VEDOLIZUMAB IN BIO-NAïVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE - AN INTERIM ANALYSIS FROM A DANISH NATIONAL COHORT STUDY

akbar molazahi  et al.

DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN’S DISEASE IN SUSTAINED, COMBINED CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL
DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN’S DISEASE IN SUSTAINED, COMBINED CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL

akbar molazahi  et al.

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

akbar molazahi  et al.

Item 1 - 4 / 4
1